Over a year after biosimilars started competing, AbbVie still holds 96% of Humira market, report says

There are nine Hu­mi­ra biosim­i­lars cur­rent­ly vy­ing to de­throne the best-sell­ing drug of all-time. And so far, none of them are com­ing any­where close.

As of Feb­ru­ary, brand-name Hu­mi­ra con­trols 96% of the adal­i­mum­ab mar­ket, ac­cord­ing to the lat­est quar­ter­ly re­port from Sam­sung Bioepis. Biosim­i­lars gained just one per­cent­age point of mar­ket share since an ear­li­er ver­sion of the Sam­sung re­port re­leased six months ago, a stark re­minder that re­al com­pe­ti­tion for Ab­b­Vie’s bi­o­log­ic could take years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.